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ABSTRACT 
 
BACKGROUND. Vitamin K antagonists (VKAs) reduce cardiovascular events (CVEs) in atrial 
fibrillation (AF) when a time in therapeutic range (TiTR) >70% is achieved. Factors affecting the 
time to achieve TR (TtTR) are unknown. 
METHODS. Prospective observational study including 1406 non-valvular AF patients starting 
VKAs followed for a mean of 31.3 months (3690 patient/year); TiTR, TtTR and SAMe-TT2R2 
score were calculated and CVEs were recorded. 
RESULTS. Median TtTR was 8.0 days (IQR 5.0-18.0). Patients with high TtTR (i.e. >75
th
 
percentile) were more likely to be in AF than in sinus rhythm at entry (Odds ratio, OR:1.423, 
p=0.011). 
Median TiTR was 60.0%; low TiTR (below median) was associated with SAMe-TT2R2 score 
(OR:1.175, p=0.001), high TtTR (>75
th
 percentile, OR:1.357, p=0.017), and number of INR checks 
(OR:0.998, p=0.049). We recorded 113 CVEs (3.1%/year), with a higher rate seen in patients with 
TtTR >75
th
 percentile compared to those below (log-rank test,p=0.006). A multivariable Cox 
regression analysis showed SAMe-TT2R2 score (HR: 1.331, p<0.001), TtTR >75
th
 percentile 
(HR:1.505, p=0.047), TiTR <70% (HR:1.931, p=0.004), number of INR checks (HR:0.988, 
p<0.001), digoxin (HR:1.855, p=0.008), proton-pump inhibitors (HR:0.452, p<0.001), were 
independently associated with CVEs. 
CONCLUSIONS. High TtTR is associated with poorer long-term quality of VKAs therapy. 
Patients with TtTR >18 days or with high SAMe-TT2R2 score should be considered for treatment 
with non-vitamin K oral anticoagulants. 
 
 
Keywords: atrial fibrillation, vitamin k antagonists, TTR, cardiovascular events. 
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INTRODUCTION 
Well-managed oral anticoagulation (OACs) with vitamin K antagonists (VKAs) is still a good 
therapeutic option for thrombo-prophylaxis in atrial fibrillation (AF) and remains widely used 
worldwide 
1
. High-quality VKAs treatment reduces cerebrovascular and cardiac complications in 
AF populations when INR values are kept in a range of 2.0-3.0 and quality of OAC is maintained 
with a good ‘time in therapeutic range’ (TiTR) 2, 3. Indeed, a TiTR>70% is associated with a low 
rate of cardiovascular events (CVEs) and bleeding complications
4, 5
. However, there is often some 
difficulty in achieving and maintain a good TiTR, and a high proportion (even up to 50%) of AF 
patients report poor-quality OAC with VKAs 
6, 7
. 
 
To predict the quality of anticoagulation therapy in patients starting VKAs, the SAMe-TT2R2 score
8
 
has been developed and validated; this score includes Sex (female), Age (<60 years), medical 
history, Treatment (interacting drugs, e.g., amiodarone), Tobacco use (within 2-years), Race (non-
white ethnicity)
9
.  Patients with a SAMe-TT2R2 score >2 were shown to be more likely to have a 
lower TiTR during VKA therapy
9
. 
 
A particularly important period of OAC treatment is the inception phase, when dosage of VKAs for 
each patient is optimised, and patients are less confident with the management of a drug requiring a 
non-fixed daily dose. Previous studies have shown a lower quality of OAC in inception cohorts 
compared to patients on long-term OAC
10-12
. Moreover, high rates of discontinuation in warfarin 
naïve patients have also been reported
13
. 
 
In addition to TiTR, a significant parameter of anticoagulation quality is the ‘Time to Therapeutic 
Range’ (TtTR), which refers to the time needed to reach the therapeutic range after the 
administration of the first dose of VKAs. In clinical practice, the TtTR may be highly variable, with 
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some patients reaching the therapeutic range after the first few tablets of VKAs, and some taking 
several days or even weeks to achieve this.  
 
The characteristics associated with high TtTR have been scarcely investigated
14
, and it is unknown 
whether the initial TtTR may influence quality of TiTR and the rate of CVEs in a long-term follow 
of AF patients.  The aim of our study was to investigate the relationship of TtTR to TiTR and CVEs 
in consecutive patients referring to an anticoagulation clinic for the prescription and management of 
VKAs therapy for non-valvular AF thromboprophylaxis. 
 
 
METHODS 
Analysis of TiTR and its determinants was a secondary endpoint of this prospective cohort study 
(clinicaltrials.gov NCT01882114). We included 2004 consecutive patients referring to the 
anticoagulation clinic of I Clinica Medica, Department of Internal Medicine and Medical 
Specialties of Sapienza University of Rome for the prescription and management of VKAs therapy 
for non-valvular AF thrombo-prophylaxis. Of these, 585 patients were warfarin-experienced 
(defined as having at least 1 dose of VKAs at entry) and were excluded from this analysis. Thus, the 
study cohort included 1419 patients starting VKAs. Exclusion criteria were prosthetic mechanical 
heart valves, severe cognitive impairment, chronic infections, autoimmune systemic disease, active 
cancer and liver insufficiency. 
 
No exclusion criteria with respect to anticoagulation prior to VKA starting was applied. Thus, both 
patients on low-molecular weight heparin (LMWH) or aspirin, or no treatment were included. The 
presence of cardiovascular risk factors was defined as previously described 
15
. Initial management 
of VKAs therapy was performed according to international guidelines 
16
, and anticoagulation 
monitoring was done with a computerized clinical decision support system (PARMA program, 
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Instrumentation Laboratory SpA, Milan). In patients taking aspirin at study entry (and no other 
indication than AF) antiplatelet drug was stopped at first dose of VKAs, while bridging LMWH 
was stopped when an INR >2 was achieved. 
 
In all patients, we calculated the TtTR, expressed as the number of days needed to achieve the 
therapeutic range since the first administration of VKAs tablet. The TiTR was calculated according 
to the method of linear interpolation described by Rosendaal et al.
17
. The SAMe-TT2R2 score was 
calculated according to its original derivation study by Apostolakis et al.
8
. We also registered the 
number of visits for INR measurement during follow-up. 
 
Definitions and adjudication of CVEs have been previously described
18
. Thus, CVEs included 
fatal/non-fatal myocardial infarction (MI) and ischemic stroke, systemic embolism, cardiac 
revascularization (coronary stent placement or coronary artery bypass graft surgery), vascular death 
and transient ischemic attack (TIA). The data on CVEs were prospectively collected and only the 
first event was used for the survival analysis. 
 
Statistical analysis 
Categorical variables were reported as counts (percentage), continuous variables were expressed as 
mean ± standard deviation or median and interquartile range (IQR), as appropriate.  Independence 
of categorical variables was tested with the χ2 test. The normal distribution of parameters was 
assessed by Kolmogorov–Smirnov test. Student unpaired t test was used to compare means.   
 
To investigate factors associated with high TtTR, we performed a multivariable logistic regression 
analysis using >75
th
 percentile of TtTR as dependent variable. As covariates, we used the composite 
SAMe-TT2R2 score, and all other variables not included in this score, such as type of rhythm at 
entry (AF vs. sinus rhythm), digoxin, proton-pump inhibitors, allopurinol, antidepressant drugs, and 
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antiepileptic drugs. Afterward, a multivariable logistic regression analysis was carried out to assess 
adjusted odds ratio (OR) for variables affecting low TiTR (below median), using the same variables 
listed above with the addition of high TtTR (>75
th
 percentile), and the number of INR checks during 
follow-up.  
 
After dividing the AF population into two groups according to low or high (≤75th or >75th 
percentile, respectively) TtTR, the cumulative incidence of CVEs was estimated using a Kaplan–
Meier product-limit estimator. Survival curves were formally compared using the log-rank test. Cox 
proportional hazards analysis was used to calculate the adjusted relative hazards of CVEs by each 
clinical variable.  Only p values <0.05 were considered as statistically significant. All tests were 
two-tailed and analyses were performed using computer software packages (SPSS-20.0, SPSS Inc.).  
 
All patients starting anticoagulation provided a written informed consent. The study protocol was 
approved by the local ethical board of Sapienza-University of Rome and was conducted according 
to principles of the Declaration of Helsinki. No extramural funding was used to support this work. 
The authors are solely responsible for the design and conduct of this study, all study analyses and 
drafting and editing of the paper. 
 
RESULTS 
TtTR and TiTR 
Mean age of patients was 73.4±9.2 years and 41.5% were women (table 1); 70.9% were started on 
warfarin, and 29.1% on acenocumarol, at physician discretion. Median TtTR was 8.0 days (IQR 
5.0-18.0). Characteristics of patients divided into those with high or low TtTR (i.e. ≤75th or >75th 
percentile) are reported in table 1; 23.5% of AF patients needed >18 days (75
th
 percentile) to 
achieve therapeutic range. The two groups were similar for all clinical characteristics, but patients 
with higher TtTR were more likely to be in AF than in sinus rhythm at entry. A multivariable 
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logistic regression analysis (table 2) confirmed this association (OR: 1.423, 95%CI 1.084-1.869, 
p=0.011). 
 
Patients were followed for a mean of 31.3±22.0 months (3690 patient/year), with no significant 
difference between patients with low or high TtTR (p=0.138). Median TiTR was 60.0% (IQR 47.0-
73.0); patients with TtTR >75
th
 percentile had significantly lower TiTR than those with low TtTR, 
spending most of time below TTR (Table 1). 
 
When we investigated factors associated with low TiTR (table 3), we found that SAMe-TT2R2 score 
(OR: 1.175, p=0.001), high TtTR (75
th
 percentile, OR: 1.357, p=0.017), and number of INR checks 
(OR: 0.998, p=0.049) were associated with low TiTR.   
 
In particular, the number of patients with TiTR <70% increased according to the SAMe-TT2R2 
score (from 56.7% for score=0, to 83.3% for a score=5, p=0.005). 
 
Cardiovascular events 
During follow-up, 13 patients were lost for survival analysis and 113 CVEs were recorded 
(3.1%/year) as follows: 13 fatal/non-fatal ischemic strokes, 10 TIAs, 27 fatal/non-fatal MIs, 25 
cardiac revascularizations, 2 systemic embolisms and 36 cardiovascular deaths. 
 
Patients with CVEs had higher SAMe-TT2R2 score (p=0.001), CHA2DS2-VASc score (p<0.001), 
and were more likely to have high TtTR (>75
th
 percentile; 22.8 vs. 32.5%, p=0.028) and low TiTR 
<70% (67.4 vs. 76.5%, p=0.026) compared to those free from events.  A higher rate of CVEs was 
found in patients with TtTR >75
th
 percentile compared to those below (log-rank test p=0.006, figure 
1).  
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On univariate Cox regression analysis, as compared to the 25
th
 percentile of TtTR, the 50
th
 
percentile was not significantly associated with CVEs (HR: 1.108, 95% CI 0.665-1.847, p=0.693); 
while the 75
th
 percentile was significantly associated with CVEs (HR:1.857, 95%CI 1.078-3.201, 
p=0.026). 
 
A multivariable Cox regression analysis (table 4) found that SAMe-TT2R2 score (HR: 1.331, 
p<0.001), TtTR >75
th
 percentile (HR:1.505, p=0.047), TiTR <70% (HR:1.931, p=0.004), number of 
INR checks (HR:0.988, p<0.001), digoxin (HR:1.855, p=0.008), proton-pump inhibitors (HR:0.452, 
p<0.001), were independently associated with CVEs. 
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DISCUSSION 
In this prospective study of AF patients starting VKAs therapy in an anticoagulation clinic, we 
found that TtTR is an important predictor for the quality of anticoagulation, as reflected by TiTR. 
Second, patients with a longer TtTR were at increased risk for CVEs. 
 
The TtTR has only been previously analysed in an ancillary analysis of the Edoxaban Versus 
Enoxaparin–Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) 
study 
14
. This trial included 2,199 patients undergoing electrical cardioversion for AF, randomized 
to enoxaparin or warfarin (n=1104). The authors found a very similar median TtTR (7 days) and a 
modest association of renal function, while no other variables were found to be significantly 
associated to TtTR. Of note, the time of observation was significantly shorter than our study, as 
patients were only followed for 28 days on the study drug and 30 days after cardioversion
14
.  
In our study, being in AF at inception of OAC, compared to sinus rhythm, was a significant risk 
factor for high TtTR. A novel finding of our study is that high TtTR is an independent predictor of 
low TiTR, suggesting that the initial OAC management as a critical factor for future quality of 
OAC. This result was confirmed even after adjustment for SAMe-TT2R2 score that is a known 
predictor of TiTR
8, 19-21
. 
 
In addition, the number of INR checks was inversely associated to TiTR, meaning that a more 
careful management of OAC would result in a better-quality control and in a lower incidence of 
CVEs.  Our findings therefore reinforce the evidence that TiTR is an important prognostic 
determinant in VKAs-treated AF patients 
2, 3, 22
, and that the SAMe-TT2R2 score has a significant 
association with CVEs
23
. This association is not surprising given that many variables included in 
this score and that affect TTR, are also associated with CVEs (i.e. smoking and cardiovascular risk 
factors). 
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A novel finding of our study is the association between proton pump inhibitors (PPI) and CVEs. 
Thus, while PPI seem not to influence TiTR
24
, their use is inversely associated with the incidence of 
CVEs. The use of PPI in patients with cardiovascular disease on antithrombotic treatment is matter 
of debate
24, 25
. However, no study examining this association in patients with AF has been reported 
thus far. It should be considered that gastroesophageal reflux disease may represent a trigger for 
AF, and that some studies have demonstrated that acid suppressive therapy by PPI may help 
ameliorate symptoms associated with AF as well as facilitate conversion to normal sinus rhythm
26
. 
This could result into a benefit on CVEs in AF patients. However, we do not know if this could be 
regarded to as a class effect, or if rather there are differences among PPIs, which deserves further 
investigation.  We also confirm our previous observation of an independent association between 
digoxin use and cardiovascular outcomes in patients with AF
18
. However, this association is still 
unresolved given the lack of randomized trial specifically including only AF patients. 
 
Our findings have clinical implications. The first is that while high-risk AF patients, such as those 
who have already experienced a stroke, are usually kept under low-molecular weight heparin until a 
stable anticoagulation is reached, most are started directly on VKAs without any bridging therapy. 
Indeed, it is necessary for them to shorten the TtTR as much as possible, considering that the first 
30 days of VKAs therapy has been associated with an increased risk of ischemic stroke in VKAs 
initiators compared to VKA-experienced patients
27
. 
 
The fact that we found only one significant predictor of TtTR suggests that other variables not 
considered in the present study may affect TtTR. This may include social and behavioural factors, 
such as adequate counselling of patients about the importance and the management of OAC with 
VKAs, awareness of the disease, family support, and changes in the perception of quality of life 
after OAC starting. Educational patient-tailored intervention was shown to improve TiTR in the 
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first 6 months of OAC
28, 29
, and it might improve also TtTR. Thus, an educational study aimed to 
explore this issue is needed.  A pharmacogenetic-guided strategy to predict optimal warfarin dosing 
has also been proposed to guide initial management of AF patients
30
. This approach was found to be 
effective as dose-finding for VKAs, but failed to reduce the number of INRs out of range
30, 31
. 
Concomitant use of daily low-dose oral vitamin K has also been suggested, with a non-significant 
effect on TiTR
32
. 
 
Finally, our findings may help clinicians in the management of AF patients starting OAC. Indeed, 
patients with high TtTR should be switched to non-vitamin K antagonist oral anticoagulants (also 
referred to as direct oral anticoagulants, DOACs), given that these agents perform better in AF 
patients with low TiTR 
33
.  Previous studies showed that the use of DOACs is associated with a 
higher adherence and persistence on OAC than VKAs. Thus, 12,307 AF patients starting VKA and 
914 starting DOAC (apixaban, dabigatran, rivaroxaban), the persistence for those with 
CHA2DS2VASc ≥ 2 was significantly higher for DOAC (83.0%) than VKA (65.3%, p< 0.0001) at 
one year 
34
. Similarly, in 1745 matched pairs of patients starting warfarin or dabigatran, persistence 
rates were higher for dabigatran than for warfarin at both 6 months (72% vs. 53%) and 1 year (63% 
vs. 39%)
35
. Finally, in 7265 patients from primary care with newly diagnosed AF, after 360 days of 
treatment, persistence was 53.1% for rivaroxaban, 47.3% for dabigatran, and 25.5% for VKAs (p< 
0.001 for rivaroxaban and dabigatran vs. VKA)
36
. 
 
Nevertheless, the limitations of our study pertain to its observational design and on the inclusion of 
only Caucasian patients. Whilst management of patients was performed according to European 
guidelines, the study was based in a single anticoagulation clinic which may limit generalisability to 
the wider population. 
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In conclusion, patients with high TtTR is associated with poorer long-term quality of VKAs 
therapy. Thus, patients with TtTR >18 days or with high SAMe-TT2R2 score should be considered 
for treatment with DOACs. 
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Figure Legends 
 
Figure 1. Kaplan-Meier curves estimate of survival free from cardiovascular events according 
to values of TtTR (grey line ≤75th percentile; black line >75th percentile). 
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Table 1. Characteristics of study population. 
 
Overall 
(n=1406) 
Low TtTR 
(≤75th 
percentile, 
n=1075) 
High TtTR 
(>75
th
 
percentile, 
n=331) 
p value 
Age (years) 73.4±9.2 73.5±9.2 73.1±9.0 0.445 
AF (vs. sinus rhythm) 64.7 62.9 70.4 0.013 
Women (%) 41.5 41.1 42.9 0.567 
Warfarin (vs. acenocumarol) 70.9 70.6 71.9 0.781 
TiTR (%) 
60.0  
(47.0-73.0) 
62.0  
(47.0-74.0) 
56.0  
(45.0-71.0) 
0.003 
Low TiTR (%, below median, 
<60%) 
47.4 45.1 54.8 0.002 
Time below TR (%) 26.5±19.4 25.4±18.6 29.8±21.6 0.001 
Time above TR (%) 14.2±12.9 14.3±13.0 13.9±12.6 0.645 
Number of INR checks 72.5±47.1 74.4±47.3 66.8±46.0 0.010 
CHA2DS2-VASc score 3.1 ±1.4 3.9±1.4 3.0±1.4 0.657 
SAMe-TT2R2 score 1.6±1.0 1.6±1.0 1.6±1.1 0.892 
HAS-BLED score 2.47±0.92 2.44±0.91 2.54±0.94 0.095 
eGFR <60 ml/min (%) 33.0 33.1 32.5 0.934 
Hypertension (%) 86.8 86.8 87.0 0.918 
Diabetes mellitus (%) 21.5 21.1 22.7 0.541 
History of cardiac events (%) 17.2 16.8 18.4 0.505 
Heart failure (%) 12.0 11.2 14.5 0.121 
History of cerebrovascular events 
(%) 
14.2 15.0 11.8 0.151 
Smoking (%) 13.4 13.3 13.8 0.848 
Pulmonary disease (%) 14.3 13.7 16.4 0.243 
Antiplatelet drugs (%) 10.8 10.0 13.3 0.105 
Amiodarone (%) 15.5 14.6 18.4 0.099 
Allopurinol (%) 7.1 7.2 6.9 0.895 
Proton-pump inhibitors (%) 40.5 39.4 44.1 0.141 
Digoxin (%) 14.2 14.2 13.9 0.928 
Antidepressant drugs (%) 9.4 9.5 9.1 0.914 
Antiepileptic drugs (%) 2.4 2.1 3.3 0.222 
Statins (%) 36.9 36.8 37.2 0.948 
 
AF: atrial fibrillation; INR: international normalized ratio; TTR: time in therapeutic range; TtTR: 
time to therapeutic range. 
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Table 2. Logistic regression analysis of factors associated to high TtTR >75
th
 percentile. 
 
 
p value OR 
95% CI for OR 
Lower Upper 
AF vs. sinus rhythm 0.011 1.423 1.084 1.869 
SAMe-TT2R2 score 0.900 1.007 0.898 1.130 
Digoxin 0.527 0.890 0.619 1.278 
Proton-pump inhibitors 0.105 1.233 0.957 1.587 
Allopurinol 0.822 0.946 0.581 1.539 
Antidepressant drugs 0.688 0.914 0.589 1.418 
Antiepileptic drugs 0.316 1.462 0.695 3.076 
 
AF: atrial fibrillation; CI: confidence interval; OR: odds ratio. 
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Table 3. Linear regression analysis of factors associated with low TiTR (below median <60%) 
 
 p value OR 95% CI 
SAMe-TT2R2 score 0.001 1.175 1.064-1.298 
High TtTR (>75
th
 percentile) 0.017 1.357 1.056-1.745 
AF vs. sinus rhythm 0.124 1.197 0.952-1.505 
Number of INR checks 0.049 0.998 0.995-1.000 
Digoxin 0.141 1.265 0.925-1.728 
Proton-pump inhibitors 0.206 1.152 0.925-1.434 
Allopurinol 0.795 0.946 0.624-1.434 
Antidepressant drugs 0.446 0.865 0.596-1.256 
Antiepileptic drugs 0.228 1.555 0.759-3.184 
 
AF: atrial fibrillation; CI: confidence interval; OR: odds ratio; TTR: time in therapeutic range; 
TtTR: time to therapeutic range. 
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Table 4. Multivariable Cox Regression analysis of risk factors for cardiovascular events. 
 
 p value HR 
95% CI for HR 
Lower Upper 
SAMe-TT2R2 score <0.001 1.331 1.142 1.553 
High TtTR (>75
th
 percentile) 0.047 1.505 1.005 2.251 
TiTR <70% 0.004 1.931 1.241 3.006 
AF vs. sinus rhythm 0.490 0.866 0.575 1.304 
Number of INR checks <0.001 0.988 0.984 0.992 
Digoxin 0.008 1.855 1.172 2.935 
Proton-pump inhibitors <0.001 0.452 0.296 0.690 
Allopurinol 0.575 1.231 0.595 2.551 
Antidepressant drugs 0.167 0.551 0.236 1.284 
Antiepileptic drugs 0.456 0.579 0.138 2.433 
 
CI: confidence interval; HR: hazard ratio; TiTR: time in therapeutic range; TtTR: time to 
therapeutic range. 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Figure 1. 
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